Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

被引：0
|
作者：
Veenstra, David L. [1 ]
Guzauskas, Gregory F. [1 ]
Spencer, Scott J. [1 ]
Felizzi, Federico [2 ]
Launonen, Aino [2 ]
Dawson, Keith [3 ]
Masaquel, Anthony [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
biosimilars; cost-effectiveness; immunochemotherapy; IBCL; indolent B-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-199
引用
收藏
页码：S280 / S280
页数：1
相关论文
共 50 条
  • [21] IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
    Hiddemann, W.
    Barbui, A. M.
    Albendea, M. A. Canales
    Cannell, P. K.
    Collins, G. P.
    Duerig, J.
    Forstpointner, R.
    Herold, M.
    Hertzberg, M.
    Klanova, M.
    Radford, J. A.
    Tobinai, K.
    Burciu, A.
    Fingerle-Rowson, G. R.
    Nielsen, T.
    Wolbers, M.
    Marcus, R. E.
    HAEMATOLOGICA, 2017, 102 : 314 - 314
  • [22] Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
    Munir, Talha
    Gaitonde, Priyanka
    Waweru, Catherine
    BLOOD, 2020, 136
  • [23] COST-EFFECTIVENESS OF ZANUBRUTINIB plus OBINUTUZUMAB FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN THE UNITED STATES
    Gaballa, S.
    Xue, M.
    Swami, S.
    Bhardwaj, A.
    Sharma, R.
    Mohseninejad, L.
    Massoudi, M.
    Yang, K.
    VALUE IN HEALTH, 2024, 27 (12)
  • [24] Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
    Cai, Hongfu
    Fang, Ling
    Lin, Jingwen
    Zheng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] COST-UTILITY OF OBINUTUZUMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
    Sun, L. A.
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A110 - A111
  • [26] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [27] COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA
    Shah, G.
    Winn, A.
    Kumar, A.
    Lin, P.
    Parsons, S.
    VALUE IN HEALTH, 2017, 20 (05) : A221 - A221
  • [28] EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK
    Rafia, R.
    Papaioannou, D.
    Stevenson, M.
    Rathbone, J.
    Woods, H. B.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A445
  • [29] Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada
    Zou, Denise
    Lee, Joseph
    Kansal, Anuraag
    Ma, Wenkang
    Harris, Mack
    Lisano, Julie
    Fenton, Keenan
    Yu, Kristina S.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 324 - 333
  • [30] Cost effectiveness of rituximab plus CVP in previously untreated indolent non-Hodgkin's lymphoma
    Maturi, B.
    Tong, W.
    Gyldmark, M.
    Creeden, J.
    Aultman, R.
    Jost, F. F.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
12345